Fig. 1 · Structure
Documents & Downloads
Riviciclib
CDK Inhibitor
Riviciclib is a potent cyclin-dependent kinase (CDK) inhibitor that selectively targets CDK9-cyclin T1, CDK4-cyclin D1, and CDK1-cyclin B, exhibiting IC50 values of 20 nM, 63 nM, and 79 nM, respectively. This compound demonstrates significant antitumor activity, especially in cisplatin-resistant cancer cells. Riviciclib is useful for research applications focused on cell cycle regulation, cancer therapy, and the development of resistance to chemotherapeutics.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 920113-02-6 |
| Applications | CDK Inhibitor |
| Formula | C21H20ClNO5 |
| Molecular Weight | 401.84 |
| Synonyms | P276-00 free base |
| SMILES | O=C1C=C(C2=C(Cl)C=CC=C2)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.